2 completed, 1 terminated. 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Terminated 1 |
| Phase 3 | 1 | Terminated 1 |
Follow TG4010: new trials by email Literature Review of TG4010 trials Research Report on TG4010
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC) TG4010, Chemotherapy, Nivolumab - Non Small Cell Lung Cancer Metastatic | Phase 2 | Completed | Transgene | 44 | 2018-01-05 | 2022-01-11 |
| TG4010 and Nivolumab in Patients With Lung Cancer TG4010, Nivolumab - Recurrent Non-Small Cell Lung Carcinoma, Stage I Non-Small Cell Lung Cancer | Phase 2 | Completed | Megan Daly, MD | 13 | 2016-12-14 | 2025-11-10 |
| Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer TG4010, placebo - Non-Small-Cell Lung Carcinoma | Phase 2 / Phase 3 | Terminated | Transgene | 222 | 2012-04-01 | 2017-01-05 |
Carcinoma, Non-Small-Cell Lung (3)
Transgene (2) · Megan Daly, MD (1)
United States (3) · Belgium (2) · France (2) · Hungary (2) · Germany (1) · Israel (1) · Italy (1) · Poland (1) · Spain (1) · United Kingdom (1)
Karen Kelly (1)
P30CA093373 (1)